Abstract:Sclerostin (Scl) is an osteocyte protein that decreases bone formation, and its inhibition by neutralizing antibodies (Scl-Ab) increases bone formation, mass and strength. We investigated the effects of Scl-Ab in mature ovariectomized (OVX) rats with a mechanistic focus on longer-term responses of osteoclasts, osteoblasts and osteocytes. Four-month-old Sprague-Dawley rats had OVX or sham surgery. Two months later, sham controls received sc vehicle while OVX rats received vehicle (OVX-Veh) or Scl-Ab (25mg/kg) once weekly for 6 or 26weeks followed by necropsy (n=12/group). Terminal blood was collected for biochemistry, non-adherent marrow cells were harvested from femurs for ex vivo osteoclast formation assays, and vertebrae and tibiae were collected for dynamic histomorphometry and mRNA analyses. Scl-Ab treatment led to progressively thicker but fewer trabeculae in the vertebra, leading to increased trabecular bone volume and reduced trabecular surfaces. Scl-Ab also increased cortical bone volume in the tibia, via early periosteal expansion and progressive endocortical contraction. Scl-Ab significantly reduced parameters of bone resorption at week 6 relative to OVX-Veh controls, including reduced serum TRACP-5b, reduced capacity of marrow cells to form osteoclasts ex vivo, and >80% reductions in vertebral trabecular and tibial endocortical eroded surfaces. At week 26, serum TRACP-5b and ex vivo osteoclast formation were no longer reduced in the Scl-Ab group, but eroded surfaces remained >80% lower than in OVX-Veh controls without evidence for altered skeletal mRNA expression of opg or rankl. Scl-Ab significantly increased parameters of bone formation at week 6 relative to OVX-Veh controls, including increases in serum P1NP and osteocalcin, and increased trabecular, endocortical and periosteal bone formation rates (BFRs). At week 26, surface-referent trabecular BFR remained significantly increased in the Scl-Ab group versus OVX-Veh controls, but after adjusting for a reduced extent of trabecular surfaces, overall (referent-independent) trabecular BFR was no longer significantly elevated. Similarly, serum P1NP and osteocalcin were no longer significantly increased in the Scl-Ab group at week 26. Tibial endocortical and periosteal BFR were increased at week 6 in the Scl-Ab group versus OVX-Veh controls, while at week 26 only endocortical BFR remained increased. The Scl-Ab group exhibited significant increments in skeletal mRNA expression of several osteocyte genes, with sost showing the greatest induction in both the tibia and vertebra. We propose that Scl-Ab administration, and/or the gains in bone volume that result, may have increased osteocytic expression of Scl as a possible means of regulating gains in bone mass.

Association of serum sclerostin levels with marrow adiposity in postmenopausal women with glucocorticoid-induced osteoporosis

SERUM C-C MOTIF LIGAND 11/EOTAXIN-1 MAY SERVE AS A CANDIDATE BIOMARKER FOR POSTMENOPAUSAL OSTEOPOROSIS

Circulating TGF-β1 Levels Are Negatively Correlated with Sclerostin Levels in Early Postmenopausal Women.

Vertebral marrow fat fraction is associated with circulating RANKL in postmenopausal females

SOST/Sclerostin impairs the osteogenesis and angiogesis in glucocorticoid-associated osteonecrosis of femoral head

Serum Concentrations of Oxytocin, DHEA and Follistatin Are Associated with Osteoporosis or Sarcopenia in Community-Dwelling Postmenopausal Women

Decreased Sclerostin Secretion in Humans and Mice With Nonalcoholic Fatty Liver Disease

Serum sclerostin levels as a diagnostic marker for osteoporosis

Lifelong genetically lowered sclerostin and risk of cardiovascular disease.

Sclerostin Antibody Mitigates Estrogen Deficiency-Inducted Marrow Lipid Accumulation Assessed By Proton Mr Spectroscopy

Sclerostin and skeletal health

The association between circulating irisin levels and osteoporosis in women: a systematic review and meta-analysis of observational studies

Risk factors for bone mineral density changes in 38 female connective tissue diseases patients who were taking glucocorticoid

Temporal changes in systemic and local expression of bone turnover markers during six months of sclerostin antibody administration to ovariectomized rats

Possible mechanisms underlying the regulation of postmenopausal osteoporosis by follicle-stimulating hormone

Effects of physical activity on sclerostin concentrations

Cardiovascular Safety and Sclerostin Inhibition

The significance of bone markers in the prediction of glucocorticoid-induced osteoporosis in patients with autoimmune diseases

Excessive glucocorticoids combined with RANKL promote the differentiation of bone marrow macrophages (BMM) into osteoclasts and accelerate the progression of osteoporosis by activating the SYK/SHP2/NF-κB signaling pathway

Sclerostin inhibition: A novel target for the treatment of postmenopausal osteoporosis

Follicle-Stimulating Hormone Increases the Risk of Postmenopausal Osteoporosis by Stimulating Osteoclast Differentiation